In the past few years, AI technology has penetrated into all aspects of the medical industry. Nearly 100 billion funds have been injected into the medical AI track in just five years, giving birth to batches of new companies.
For these companies, the most important proposition today is how to stand out from the fierce competition under the particularity of the medical industry and strict regulatory supervision, and get rid of the dilemma of “commercial broken chain” of only bleeding, no blood transfusion, and no return of blood ?
The core of this problem is to touch the difficulties and pains deep in the digital transformation of the medical industry, and improve the usability, feasibility and replicability of products.
Taking medical imaging AI products as an example, Professor Liu Shiyuan, director of the Department of Radiology and Diagnostics at Shanghai Changzheng Hospital, once admitted that there are three major problems with current AI imaging products: first, there are relatively few products available; second, product performance is unreliable; Fits well into existing workflows, and clinical utility is not strong.
AI and digital applications in the medical industry have never been smooth. Fortunately, there are still some excellent companies that have devoted themselves to refining product solutions, creating benchmark cases one after another, improving the quality and efficiency of medical institutions, improving the work and treatment experience for doctors and patients, and providing the most cutting-edge and practical technological weapons.
To this end, Leifeng.com launched the selection of the 2022 “Flying into the Earth and Going to the Sea” annual science and technology list. 49 benchmarking companies were selected from 12 vertical fields including , industrial intelligent manufacturing, automotive technology, enterprise services, commercial robots, future interaction, consumer electronics, chips, medical AI and digitalization, cloud and data infrastructure.
Among them, in the field of medical AI and digitalization, Ping An, InferMed, Shentou Medical, United Imaging, and Molecule Heart were successfully selected into the local list, and won the Life Insurance Digital Transformation Empowerment Benchmark Award and the Lung AI Solution in this field respectively. Landing Benchmarking Award, Brain AI Solution Landing Benchmarking Award, Cardiovascular CTA Innovative Product Benchmarking Award, AI Pharmaceutical Technology Benchmarking Award.
Life Insurance Digital Transformation Empowerment Benchmark Award: Ping An of China
As an important practice of technology empowering finance, digitalization is a major trend in the current development and progress of the industry.
Since 2019, Ping An Life Insurance has taken the lead in exploring digital transformation, hoping to use technological empowerment to create a new model of digital life insurance. At present, with the help of digital reforms covering channels, products, operations, management, operations and other modules, the reforms in channel management, product development management, service operation, and operation management have been completed, and improvements in experience, efficiency, and Risk prevention, cost reduction and other results.
Ping An Life takes digitization as the core means, and helps understand the overall picture of operations, locate problems, predict trends, and create a “smart operation” model by sorting out the neural network panorama of life insurance operation and management.
In addition, risk prevention is an eternal theme in the financial industry. Ping An Life fully relies on digital capabilities to create a digital risk prevention system, and applies digital technology to the entire process of risk monitoring, identification, early warning and disposal to enhance risk prevention and control capabilities.
Talents are the foundation of technological innovation and application. Ping An Life currently has more than 100 people with experience in technology and finance, more than 1,000 technology professionals, including more than 300 experts in data governance, architecture design, model algorithms, big data, artificial intelligence, network security, etc. . The scientific and technological team has achieved good results in domestic and foreign technical competitions for many times; several digital projects have been recognized by the market, and won the Shenzhen “Financial Innovation Award”, the 21st Century Business Herald “Annual Excellent Digital Transformation” Case Award and other awards.
The road to digital transformation of the life insurance industry is “long and difficult”, but it must be “coming soon”.
Pulmonary AI Solution Landing Benchmark Award: InferMed
Infervision Medical was established in 2016, focusing on the field of AI medical care, and is committed to building a hospital-level AI international leading brand. It is a world-leading artificial intelligence medical technology company.
As the world’s first and only AI medical technology company whose products have been approved by the four major markets of US FDA, EU CE, Japan PMDA and China NMPA, Infer Medical has covered more than 900 medical institutions in nearly 20 countries around the world.
Inference Medical adopts the strategic layout of “one horizontal and one vertical” and “internationalization” to create a rich three-dimensional product pipeline. The company’s product pipeline covers cancer, infectious diseases, cardiovascular and cerebrovascular diseases, trauma and other disease fields horizontally; vertically along the patient diagnosis and treatment process, it provides smart solutions for the whole process of “screening, diagnosis, treatment, management, and research”.
A series of chest AI solutions of Infervision Medical, covering auxiliary screening and detection of various chest diseases, related products (including InferRead® CT Lung lung disease intelligent solution, InferRead® CT Pneumonia pneumonia disease intelligent solution and InferRead® CT Bone thoracic fracture intelligent solution) have obtained the three types of medical device certification from the State Drug Administration, referred to as “three types of chest and lungs”. One-stop accurate and efficient diagnosis of various chest diseases can be satisfied with one CT scan. Screening for more diseases can be achieved without increasing medical expenses, improving the efficiency and output of inspections, and facilitating accurate and comprehensive diagnosis by doctors without increasing the radiation risk of patients.
Not only in the field of chest and lungs, but also the AI products of Inference Medical for Stroke have obtained the US FDA certification and China’s NMPA Class III certificate, becoming a “Sino-US dual certification” product, which has been unanimously affirmed by domestic and foreign drug regulatory agencies.
Brain AI Solution Landing Benchmark Award: Shentou Medical
Subtle Medical is an innovative company that is deeply involved in AI-driven medical imaging services. Starting from the AI+ medical imaging process, combined with deep learning and image reconstruction and enhancement technology, it optimizes the quality, process and efficiency of medical imaging, and truly realizes cost savings and efficiency increases for customers.
Shentou Medical has the only AI medical imaging product in the industry that has passed global approvals such as China’s NMPA, US FDA and European CE. Applying AI technology to imaging can solve image quality and efficiency problems from the source, optimize the process of data reconstruction into images, and speed up MRI and PET inspections by at least 4-10 times.
In 2022, Shentou Medical will maintain efficient development, and the pace of commercialization will be significantly accelerated. In 2021, Shentou Medical will still achieve a 400% revenue growth under the background of the epidemic. Compared with Q4 in 2021, Shentou Medical’s global clinical service business volume has achieved more than five-fold growth, and its business map continues to expand.
So far, Shentou Medical has obtained certifications from the United States, Europe, China, South America, Canada, Australia, New Zealand, Singapore and other places. It has deployed nearly 500 top hospitals and imaging centers around the world, and has successively reached agreements worth tens of millions of dollars with Siemens and Bayer. cooperate.
At present, a number of regulations, industry endorsements and extensive implementation have established Shentou Medical as a global leader in the field of AI-based medical image acquisition and process optimization.
Cardiovascular CTA Innovation Product Benchmark Award: United Imaging
United Imaging was established in Shanghai at the end of 2017, and it is an important strategic layout of the United Imaging Group in the field of artificial intelligence. Relying on United Imaging’s high-performance software and hardware technology platforms and resource advantages, United Imaging has become a medical AI company that can provide multi-scenario, multi-disease, full-process, and integrated intelligent solutions, empowering equipment, clinical and scientific research, Covering multiple AI application scenarios such as hospital-level management, medical innovation ecology, workflow optimization, precise diagnosis and treatment, and personal health management.
As a leading medical AI company, United Imaging has gathered a group of top medical AI talents from home and abroad. Up to now, United Imaging has completed the research and development of dozens of AI applications, which have been implemented in more than a thousand hospitals across the country, running through the entire process of diagnosis and treatment. field. In 2022, United Imaging has successively won major national projects in the fields of heart and brain.
United Imaging intelligent CTA coronary artery intelligent analysis system focuses on clinical pain points, helping doctors to achieve coronary artery reconstruction and diagnosis in one go. The system can accurately reconstruct coronary arteries and support 360° rotating observation of blood vessels. It is also suitable for special and complicated cases such as complete occlusion, abnormal origin, postoperative bypass, coronary artery fistula, etc. At the same time, the system supports blood vessel and centerline editing. Provide plaque analysis and stenosis assessment, intelligent identification of stents and myocardial bridges, intelligent analysis of calcification scores, plaque components, pericoronal fat FAI value, FFR score, TAG value, one-click film layout and filing, and generate customized structured reports , the overall workflow time is about 5 minutes, which saves about 70% of the time compared with the traditional workflow.
Create a difference for a healthy Datong. In the future, United Imaging will continue to empower and improve the efficiency of doctors and medical equipment, and work together with users and partners to achieve a win-win situation, making AI the best partner for users.
AI Pharmaceutical Technology Benchmark Award: Molecular Heart
Molecular Heart is an industry-leading AI protein design platform company, committed to bringing revolutionary changes to the discovery, optimization and design of proteins through top-level artificial intelligence algorithms, so as to accelerate the entire process of drug research and development, and promote industrial and agricultural production, material design and Environmental improvement and other innovations in all fields.
Professor Xu Jinbo, the founder of Molecular Heart, began to engage in protein research more than 20 years ago. The RaptorX-Contact method he developed in 2016 proved for the first time in the world that deep learning can greatly improve protein structure prediction. This method was later borrowed by Google’s DeepMind to develop the AlphaFold series of algorithms.
In less than a year since its establishment, Molecule Heart has launched the industry’s first fully functional AI protein prediction and design platform “MoleculeOS”, which has filled the gap that there is no fully functional AI protein design and optimization platform in my country. MoleculeOS uses data-driven deep learning methods to quickly identify and generate the most suitable proteins, and project laboratory research results to industrial applications on a large scale. This platform is crucial to the technology research and development and industrial application in the protein field, and is the “infrastructure” of the bio-economy era.
Based on the Molecule platform, Molecular Heart has made more than ten world-leading technological breakthroughs, including protein de novo design, protein optimization, antibody redesign, protein and complex structure prediction, protein-protein docking, protein side chain prediction, and protein function prediction , protein language model and other key algorithms and modules, the calculation results far exceed those of global players such as AlphaFold2, and pioneered new protein optimization and design schemes such as precise reconstruction of CDR regions and generation of protein ligands without templates, realizing “on-demand transformation” “, and even “design from scratch” proteins, using AI technology to make protein design on-demand, predictable, and programmable.
This article is reproduced from: https://www.leiphone.com/category/healthhai/xi5d4BOBmIzuXWSp.html
This site is only for collection, and the copyright belongs to the original author.